Single-center study on features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors

CONCLUSIONS: A high prevalence of rheumatic IMIDs is observed in patients with MPNs and JAK2 (V617F) mutation. JAK inhibitors might be a targeted therapy option in these patients.PMID:38044168 | DOI:10.1016/j.ejim.2023.11.019

Source: European Journal of Internal Medicine - December 3, 2023 Category: Internal Medicine Authors: Carmen Álvarez-Reguera Diana Prieto-Pe ña Alba Herrero-Morant Lara S ánchez-Bilbao Ana Batlle-L ópez Sara Fern ández-López Nerea Paz-Gandiaga Ricardo Blanco Source Type: research